| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 53 | 2026 | 800 | 3.460 |
Why?
|
| Aging | 43 | 2026 | 680 | 2.860 |
Why?
|
| Brain | 43 | 2025 | 707 | 2.670 |
Why?
|
| Cognitive Dysfunction | 31 | 2026 | 449 | 2.660 |
Why?
|
| Cognition Disorders | 36 | 2019 | 437 | 2.650 |
Why?
|
| Aged, 80 and over | 98 | 2026 | 2152 | 2.040 |
Why?
|
| Aged | 112 | 2026 | 4000 | 1.880 |
Why?
|
| Female | 142 | 2026 | 6974 | 1.820 |
Why?
|
| Male | 137 | 2025 | 6815 | 1.800 |
Why?
|
| Cognition | 30 | 2024 | 641 | 1.680 |
Why?
|
| Humans | 165 | 2026 | 12240 | 1.610 |
Why?
|
| Dementia | 15 | 2022 | 236 | 1.330 |
Why?
|
| Parkinson Disease | 21 | 2017 | 314 | 1.200 |
Why?
|
| Longitudinal Studies | 37 | 2020 | 651 | 1.100 |
Why?
|
| Neuropsychological Tests | 33 | 2022 | 558 | 0.920 |
Why?
|
| Nervous System Diseases | 6 | 2023 | 60 | 0.830 |
Why?
|
| Cohort Studies | 32 | 2024 | 827 | 0.790 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2023 | 464 | 0.780 |
Why?
|
| Parkinsonian Disorders | 6 | 2019 | 91 | 0.720 |
Why?
|
| Tourette Syndrome | 5 | 2009 | 8 | 0.700 |
Why?
|
| Hallucinations | 5 | 2011 | 19 | 0.630 |
Why?
|
| Models, Statistical | 3 | 2019 | 60 | 0.580 |
Why?
|
| Severity of Illness Index | 16 | 2019 | 423 | 0.560 |
Why?
|
| Autopsy | 17 | 2023 | 174 | 0.560 |
Why?
|
| Cerebral Amyloid Angiopathy | 6 | 2023 | 57 | 0.550 |
Why?
|
| Brain Infarction | 5 | 2021 | 36 | 0.540 |
Why?
|
| White Matter | 4 | 2022 | 52 | 0.540 |
Why?
|
| Independent Living | 9 | 2022 | 137 | 0.530 |
Why?
|
| Movement Disorders | 5 | 2012 | 32 | 0.470 |
Why?
|
| Disease Progression | 17 | 2020 | 290 | 0.460 |
Why?
|
| Hippocampus | 7 | 2022 | 97 | 0.460 |
Why?
|
| Motor Activity | 6 | 2018 | 175 | 0.450 |
Why?
|
| Middle Aged | 34 | 2025 | 4043 | 0.440 |
Why?
|
| Movement | 8 | 2018 | 58 | 0.430 |
Why?
|
| Stroke | 5 | 2019 | 117 | 0.420 |
Why?
|
| DNA-Binding Proteins | 7 | 2022 | 151 | 0.400 |
Why?
|
| Spinal Cord | 3 | 2018 | 46 | 0.400 |
Why?
|
| Motor Skills | 6 | 2021 | 32 | 0.390 |
Why?
|
| Risk Factors | 19 | 2021 | 1049 | 0.390 |
Why?
|
| Adult | 24 | 2025 | 3557 | 0.380 |
Why?
|
| Memory, Episodic | 4 | 2022 | 43 | 0.370 |
Why?
|
| Sleep Wake Disorders | 3 | 2012 | 58 | 0.370 |
Why?
|
| Memory, Short-Term | 8 | 2022 | 53 | 0.360 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 25 | 0.360 |
Why?
|
| Neurodegenerative Diseases | 3 | 2018 | 60 | 0.340 |
Why?
|
| Disability Evaluation | 8 | 2019 | 105 | 0.340 |
Why?
|
| Prospective Studies | 13 | 2022 | 817 | 0.340 |
Why?
|
| Refusal to Participate | 1 | 2010 | 2 | 0.330 |
Why?
|
| Cerebral Infarction | 7 | 2020 | 63 | 0.320 |
Why?
|
| Disabled Persons | 4 | 2012 | 47 | 0.320 |
Why?
|
| Mortality | 1 | 2010 | 37 | 0.320 |
Why?
|
| Brain Diseases | 2 | 2020 | 30 | 0.320 |
Why?
|
| F2-Isoprostanes | 1 | 2010 | 6 | 0.310 |
Why?
|
| Huntington Disease | 2 | 2008 | 29 | 0.310 |
Why?
|
| Piperidines | 2 | 2006 | 10 | 0.310 |
Why?
|
| Quality of Life | 4 | 2013 | 261 | 0.300 |
Why?
|
| Psychometrics | 3 | 2010 | 95 | 0.300 |
Why?
|
| SNARE Proteins | 2 | 2021 | 5 | 0.300 |
Why?
|
| Exercise | 3 | 2021 | 233 | 0.300 |
Why?
|
| Nerve Tissue Proteins | 3 | 2016 | 87 | 0.290 |
Why?
|
| Literacy | 2 | 2021 | 13 | 0.290 |
Why?
|
| Educational Status | 5 | 2021 | 130 | 0.290 |
Why?
|
| Neuropathology | 3 | 2018 | 42 | 0.290 |
Why?
|
| Antipsychotic Agents | 2 | 2006 | 29 | 0.280 |
Why?
|
| Neuroimaging | 4 | 2022 | 66 | 0.280 |
Why?
|
| Motor Disorders | 2 | 2020 | 13 | 0.270 |
Why?
|
| Temporal Lobe | 2 | 2018 | 29 | 0.270 |
Why?
|
| Regression Analysis | 8 | 2021 | 105 | 0.270 |
Why?
|
| Gait | 4 | 2019 | 195 | 0.270 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 726 | 0.260 |
Why?
|
| Cognitive Reserve | 2 | 2021 | 12 | 0.260 |
Why?
|
| Cognitive Aging | 2 | 2018 | 34 | 0.250 |
Why?
|
| Lewy Bodies | 7 | 2019 | 96 | 0.250 |
Why?
|
| Activities of Daily Living | 6 | 2012 | 182 | 0.250 |
Why?
|
| Neurologic Examination | 6 | 2020 | 49 | 0.250 |
Why?
|
| Indans | 1 | 2006 | 5 | 0.250 |
Why?
|
| Chorea | 1 | 2006 | 3 | 0.250 |
Why?
|
| Neurofibrillary Tangles | 5 | 2022 | 64 | 0.250 |
Why?
|
| Comorbidity | 8 | 2018 | 209 | 0.240 |
Why?
|
| tau Proteins | 4 | 2022 | 88 | 0.240 |
Why?
|
| Seasons | 1 | 2006 | 12 | 0.240 |
Why?
|
| Recovery of Function | 1 | 2006 | 118 | 0.240 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 6 | 0.230 |
Why?
|
| Apolipoproteins E | 5 | 2022 | 100 | 0.230 |
Why?
|
| Chicago | 8 | 2017 | 453 | 0.220 |
Why?
|
| Memory Disorders | 5 | 2019 | 68 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 79 | 0.220 |
Why?
|
| Autoimmunity | 1 | 2025 | 8 | 0.220 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 38 | 0.220 |
Why?
|
| Time | 1 | 2005 | 10 | 0.220 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 400 | 0.220 |
Why?
|
| DNA Methylation | 2 | 2015 | 93 | 0.210 |
Why?
|
| Lewy Body Disease | 4 | 2018 | 54 | 0.210 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2021 | 36 | 0.200 |
Why?
|
| HIV Infections | 2 | 2017 | 256 | 0.200 |
Why?
|
| Death | 2 | 2021 | 24 | 0.200 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2014 | 19 | 0.200 |
Why?
|
| Incidence | 9 | 2018 | 338 | 0.200 |
Why?
|
| Algorithms | 4 | 2013 | 169 | 0.200 |
Why?
|
| Video Recording | 2 | 2003 | 16 | 0.200 |
Why?
|
| Plaque, Amyloid | 2 | 2015 | 45 | 0.190 |
Why?
|
| Psychomotor Performance | 7 | 2020 | 85 | 0.190 |
Why?
|
| Neurons | 3 | 2015 | 164 | 0.190 |
Why?
|
| Atherosclerosis | 1 | 2023 | 20 | 0.190 |
Why?
|
| Low Back Pain | 3 | 1999 | 69 | 0.190 |
Why?
|
| Mental Recall | 2 | 2020 | 24 | 0.190 |
Why?
|
| Adolescent | 7 | 2010 | 989 | 0.190 |
Why?
|
| Flavonols | 1 | 2022 | 5 | 0.190 |
Why?
|
| Residence Characteristics | 5 | 2016 | 87 | 0.190 |
Why?
|
| Hypertension | 2 | 2022 | 85 | 0.180 |
Why?
|
| Entorhinal Cortex | 2 | 2017 | 7 | 0.180 |
Why?
|
| Crime Victims | 1 | 2022 | 16 | 0.180 |
Why?
|
| Polymorphism, Genetic | 3 | 2011 | 33 | 0.180 |
Why?
|
| Synapses | 2 | 2012 | 15 | 0.180 |
Why?
|
| Health Resources | 1 | 2002 | 14 | 0.180 |
Why?
|
| Anxiety Disorders | 2 | 2013 | 84 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 18 | 0.180 |
Why?
|
| Accelerometry | 2 | 2019 | 48 | 0.180 |
Why?
|
| Kidney | 2 | 2009 | 87 | 0.180 |
Why?
|
| Hospitals | 1 | 2002 | 68 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 42 | 0.180 |
Why?
|
| Amyloid | 3 | 2017 | 20 | 0.180 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2022 | 40 | 0.170 |
Why?
|
| Gait Disorders, Neurologic | 4 | 2009 | 67 | 0.170 |
Why?
|
| Cause of Death | 1 | 2021 | 32 | 0.170 |
Why?
|
| Statistics, Nonparametric | 5 | 2010 | 72 | 0.170 |
Why?
|
| Psychology | 1 | 2021 | 13 | 0.170 |
Why?
|
| Acculturation | 1 | 2021 | 9 | 0.170 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2021 | 7 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2021 | 25 | 0.160 |
Why?
|
| Social Environment | 1 | 2021 | 38 | 0.160 |
Why?
|
| Serial Learning | 1 | 2020 | 4 | 0.160 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 5 | 0.160 |
Why?
|
| Prosthesis Failure | 1 | 2002 | 229 | 0.160 |
Why?
|
| Music | 1 | 2021 | 11 | 0.160 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 19 | 0.160 |
Why?
|
| Interpersonal Relations | 2 | 2014 | 48 | 0.150 |
Why?
|
| United States | 7 | 2021 | 989 | 0.150 |
Why?
|
| Sleep | 3 | 2012 | 155 | 0.150 |
Why?
|
| Hip Prosthesis | 1 | 2002 | 248 | 0.150 |
Why?
|
| Surveys and Questionnaires | 6 | 2017 | 546 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 191 | 0.150 |
Why?
|
| Manipulation, Orthopedic | 1 | 1999 | 7 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 10 | 0.150 |
Why?
|
| Loneliness | 2 | 2017 | 31 | 0.150 |
Why?
|
| Linear Models | 5 | 2020 | 115 | 0.150 |
Why?
|
| Proportional Hazards Models | 7 | 2016 | 161 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 21 | 0.150 |
Why?
|
| Cerebral Arteries | 2 | 2016 | 18 | 0.150 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2016 | 24 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 20 | 0.140 |
Why?
|
| Hypoventilation | 2 | 2010 | 30 | 0.140 |
Why?
|
| Motor Neurons | 1 | 2018 | 4 | 0.140 |
Why?
|
| Age Factors | 6 | 2019 | 350 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 3 | 2020 | 60 | 0.140 |
Why?
|
| Pain | 2 | 2010 | 193 | 0.140 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2018 | 4 | 0.140 |
Why?
|
| Apolipoprotein E4 | 3 | 2015 | 106 | 0.140 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2019 | 12 | 0.140 |
Why?
|
| Diet, Mediterranean | 1 | 2019 | 27 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 28 | 0.140 |
Why?
|
| Child | 5 | 2010 | 614 | 0.140 |
Why?
|
| Amyloid beta-Peptides | 4 | 2024 | 98 | 0.140 |
Why?
|
| Geriatric Assessment | 5 | 2018 | 96 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2019 | 90 | 0.140 |
Why?
|
| Cholecystokinin | 2 | 2011 | 5 | 0.140 |
Why?
|
| Actigraphy | 3 | 2015 | 41 | 0.140 |
Why?
|
| Organ Size | 2 | 2015 | 41 | 0.140 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2002 | 349 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Proteomics | 3 | 2026 | 39 | 0.140 |
Why?
|
| Muscle Strength | 3 | 2019 | 46 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2018 | 51 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 2018 | 32 | 0.130 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2018 | 14 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2011 | 132 | 0.130 |
Why?
|
| Biomarkers | 4 | 2025 | 294 | 0.130 |
Why?
|
| Learning | 1 | 2018 | 34 | 0.130 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 278 | 0.130 |
Why?
|
| Microvessels | 1 | 2017 | 11 | 0.130 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 15 | 0.130 |
Why?
|
| Postural Balance | 1 | 2018 | 62 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 695 | 0.130 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 6 | 0.120 |
Why?
|
| Double-Blind Method | 6 | 2018 | 166 | 0.120 |
Why?
|
| Knee Joint | 1 | 2019 | 284 | 0.120 |
Why?
|
| Biostatistics | 1 | 2016 | 3 | 0.120 |
Why?
|
| Postmortem Changes | 1 | 2016 | 17 | 0.120 |
Why?
|
| Pregnancy, Multiple | 1 | 1996 | 2 | 0.120 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1996 | 4 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 1996 | 10 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 218 | 0.120 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 2 | 0.120 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 2 | 0.120 |
Why?
|
| Memory | 4 | 2020 | 112 | 0.120 |
Why?
|
| Weight Gain | 1 | 1996 | 30 | 0.110 |
Why?
|
| Computer Simulation | 3 | 2016 | 90 | 0.110 |
Why?
|
| Cumulative Trauma Disorders | 2 | 1995 | 6 | 0.110 |
Why?
|
| Genome, Human | 1 | 2015 | 21 | 0.110 |
Why?
|
| Misoprostol | 1 | 1995 | 2 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 1995 | 8 | 0.110 |
Why?
|
| Ibuprofen | 1 | 1995 | 5 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 43 | 0.110 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 7 | 0.110 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 7 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 14 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 28 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 33 | 0.110 |
Why?
|
| Placebo Effect | 2 | 2006 | 5 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 43 | 0.110 |
Why?
|
| Wrist | 1 | 1994 | 11 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2022 | 64 | 0.110 |
Why?
|
| Sclerosis | 3 | 2020 | 32 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 1995 | 61 | 0.100 |
Why?
|
| Illinois | 3 | 2017 | 110 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 110 | 0.100 |
Why?
|
| Muscle Rigidity | 2 | 2006 | 5 | 0.100 |
Why?
|
| Genotype | 5 | 2015 | 169 | 0.100 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2006 | 8 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2004 | 19 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 20 | 0.100 |
Why?
|
| Risk | 4 | 2015 | 97 | 0.100 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 5 | 0.100 |
Why?
|
| Atrophy | 3 | 2012 | 29 | 0.100 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 45 | 0.100 |
Why?
|
| Prevalence | 3 | 2018 | 175 | 0.100 |
Why?
|
| Estrogens | 3 | 2001 | 10 | 0.100 |
Why?
|
| Logistic Models | 5 | 2016 | 196 | 0.090 |
Why?
|
| Alleles | 5 | 2015 | 119 | 0.090 |
Why?
|
| Vision Disorders | 1 | 2012 | 8 | 0.090 |
Why?
|
| Tics | 2 | 2003 | 2 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 38 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 12 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2013 | 42 | 0.090 |
Why?
|
| Walking | 3 | 2022 | 108 | 0.090 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2020 | 29 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 81 | 0.090 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Qa-SNARE Proteins | 1 | 2012 | 3 | 0.090 |
Why?
|
| Models, Psychological | 1 | 2012 | 37 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 324 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2012 | 69 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2006 | 1478 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2009 | 320 | 0.090 |
Why?
|
| Abnormalities, Multiple | 2 | 2010 | 11 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2010 | 17 | 0.090 |
Why?
|
| Myoclonus | 2 | 2002 | 2 | 0.090 |
Why?
|
| Wakefulness | 1 | 2011 | 39 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2011 | 14 | 0.090 |
Why?
|
| Brazil | 2 | 2021 | 17 | 0.090 |
Why?
|
| Homeodomain Proteins | 2 | 2010 | 47 | 0.090 |
Why?
|
| Receptors, Complement 3b | 1 | 2011 | 8 | 0.080 |
Why?
|
| Physical Therapy Modalities | 2 | 2022 | 31 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2010 | 105 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2012 | 77 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2010 | 19 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 4 | 2016 | 40 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2021 | 225 | 0.080 |
Why?
|
| Animals | 4 | 2021 | 2092 | 0.080 |
Why?
|
| Substantia Innominata | 1 | 2009 | 4 | 0.080 |
Why?
|
| Rats | 3 | 2021 | 407 | 0.080 |
Why?
|
| Amnesia | 1 | 2009 | 10 | 0.080 |
Why?
|
| Frail Elderly | 1 | 2010 | 19 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2016 | 221 | 0.070 |
Why?
|
| Somatosensory Disorders | 1 | 2009 | 5 | 0.070 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 13 | 0.070 |
Why?
|
| Lung | 1 | 2009 | 76 | 0.070 |
Why?
|
| Vibration | 1 | 2009 | 18 | 0.070 |
Why?
|
| Adoption | 2 | 1979 | 2 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 26 | 0.070 |
Why?
|
| Fertility | 2 | 1979 | 12 | 0.070 |
Why?
|
| Mobility Limitation | 1 | 2009 | 36 | 0.070 |
Why?
|
| Analysis of Variance | 5 | 2011 | 125 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2018 | 295 | 0.070 |
Why?
|
| Dystonic Disorders | 1 | 2008 | 1 | 0.070 |
Why?
|
| Interviews as Topic | 2 | 2021 | 66 | 0.070 |
Why?
|
| Muscle Weakness | 1 | 2008 | 7 | 0.070 |
Why?
|
| Muscle Contraction | 1 | 2008 | 52 | 0.070 |
Why?
|
| Death, Sudden | 1 | 2008 | 5 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2021 | 1467 | 0.070 |
Why?
|
| Prognosis | 2 | 2019 | 363 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 122 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2007 | 22 | 0.060 |
Why?
|
| Dyskinesias | 1 | 2006 | 5 | 0.060 |
Why?
|
| Receptors, AMPA | 1 | 2006 | 7 | 0.060 |
Why?
|
| Dioxoles | 1 | 2006 | 6 | 0.060 |
Why?
|
| Nootropic Agents | 1 | 2006 | 7 | 0.060 |
Why?
|
| Child Behavior Disorders | 1 | 2006 | 13 | 0.060 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2026 | 4 | 0.060 |
Why?
|
| Darkness | 1 | 2006 | 6 | 0.060 |
Why?
|
| Infant | 2 | 2023 | 277 | 0.060 |
Why?
|
| Statistics as Topic | 3 | 2017 | 51 | 0.060 |
Why?
|
| Twins | 2 | 1996 | 6 | 0.060 |
Why?
|
| Motor Cortex | 1 | 2006 | 9 | 0.060 |
Why?
|
| Light | 1 | 2006 | 36 | 0.060 |
Why?
|
| Awareness | 1 | 2006 | 21 | 0.060 |
Why?
|
| Weights and Measures | 1 | 2005 | 2 | 0.060 |
Why?
|
| Depression | 2 | 2014 | 229 | 0.060 |
Why?
|
| Observer Variation | 1 | 2005 | 47 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 37 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 64 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2012 | 34 | 0.060 |
Why?
|
| Neopterin | 1 | 2025 | 4 | 0.060 |
Why?
|
| Glycosylation | 1 | 2025 | 12 | 0.060 |
Why?
|
| West Nile Fever | 1 | 2005 | 1 | 0.060 |
Why?
|
| CpG Islands | 2 | 2015 | 30 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2025 | 29 | 0.050 |
Why?
|
| Acute Disease | 2 | 2002 | 90 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2005 | 27 | 0.050 |
Why?
|
| Progesterone | 2 | 2001 | 10 | 0.050 |
Why?
|
| Fragile X Syndrome | 1 | 2006 | 140 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2009 | 115 | 0.050 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2004 | 2 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2011 | 182 | 0.050 |
Why?
|
| Research Design | 2 | 2021 | 79 | 0.050 |
Why?
|
| Pregnancy | 4 | 1996 | 193 | 0.050 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2004 | 3 | 0.050 |
Why?
|
| Menstrual Cycle | 2 | 2001 | 15 | 0.050 |
Why?
|
| Mental Status Schedule | 2 | 2018 | 38 | 0.050 |
Why?
|
| Spinal Stenosis | 1 | 2004 | 15 | 0.050 |
Why?
|
| Fibromyalgia | 1 | 2004 | 13 | 0.050 |
Why?
|
| Occupational Diseases | 2 | 1995 | 11 | 0.050 |
Why?
|
| Pandemics | 1 | 2025 | 126 | 0.050 |
Why?
|
| Heterozygote | 2 | 2015 | 72 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 8 | 0.050 |
Why?
|
| Syndrome | 3 | 2010 | 40 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2004 | 18 | 0.050 |
Why?
|
| Spinal Cord Diseases | 1 | 2004 | 21 | 0.050 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 24 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2003 | 2 | 0.050 |
Why?
|
| Walkers | 1 | 2003 | 1 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2020 | 28 | 0.050 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 182 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2011 | 256 | 0.050 |
Why?
|
| Ticlopidine | 1 | 2003 | 1 | 0.050 |
Why?
|
| Nerve Growth Factor | 1 | 2003 | 25 | 0.050 |
Why?
|
| Health Status | 1 | 2003 | 96 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2003 | 186 | 0.050 |
Why?
|
| Aspirin | 1 | 2003 | 20 | 0.050 |
Why?
|
| Neuroticism | 2 | 2013 | 13 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 37 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Quercetin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Kaempferols | 1 | 2022 | 5 | 0.050 |
Why?
|
| Sex Factors | 2 | 2015 | 229 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 10 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2009 | 73 | 0.050 |
Why?
|
| Reference Values | 3 | 2012 | 103 | 0.050 |
Why?
|
| Eating | 1 | 2022 | 25 | 0.050 |
Why?
|
| Fraud | 1 | 2022 | 6 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 26 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 252 | 0.050 |
Why?
|
| Equipment Failure Analysis | 1 | 2002 | 32 | 0.050 |
Why?
|
| Device Removal | 1 | 2002 | 32 | 0.050 |
Why?
|
| Corrosion | 1 | 2002 | 54 | 0.050 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2002 | 6 | 0.050 |
Why?
|
| Executive Function | 1 | 2022 | 47 | 0.050 |
Why?
|
| Alloys | 1 | 2002 | 51 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 17 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2002 | 39 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2016 | 12 | 0.040 |
Why?
|
| Anthocyanins | 1 | 2022 | 5 | 0.040 |
Why?
|
| Antiparkinson Agents | 1 | 2002 | 18 | 0.040 |
Why?
|
| Fruit | 1 | 2022 | 18 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 99 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 94 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 47 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2002 | 195 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 45 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 124 | 0.040 |
Why?
|
| Spatial Processing | 1 | 2021 | 4 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 11 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2021 | 6 | 0.040 |
Why?
|
| Receptors, Dopamine | 1 | 2001 | 5 | 0.040 |
Why?
|
| Hypoxia, Brain | 1 | 2001 | 1 | 0.040 |
Why?
|
| Mathematics | 1 | 2021 | 25 | 0.040 |
Why?
|
| Writing | 1 | 2021 | 10 | 0.040 |
Why?
|
| Reading | 1 | 2021 | 12 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2001 | 44 | 0.040 |
Why?
|
| Pergolide | 1 | 2000 | 1 | 0.040 |
Why?
|
| Thiazoles | 1 | 2000 | 8 | 0.040 |
Why?
|
| Hypotension, Orthostatic | 1 | 2000 | 6 | 0.040 |
Why?
|
| Dopamine Agonists | 1 | 2000 | 10 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 11 | 0.040 |
Why?
|
| Indoles | 1 | 2000 | 21 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 171 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2014 | 46 | 0.040 |
Why?
|
| Microcirculation | 2 | 2011 | 15 | 0.040 |
Why?
|
| Family | 1 | 2021 | 52 | 0.040 |
Why?
|
| Sensory Aids | 1 | 2000 | 1 | 0.040 |
Why?
|
| Cues | 1 | 2000 | 16 | 0.040 |
Why?
|
| Amyloid Neuropathies | 1 | 2020 | 3 | 0.040 |
Why?
|
| Space Perception | 1 | 2019 | 10 | 0.040 |
Why?
|
| Manipulation, Spinal | 1 | 1999 | 2 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 24 | 0.040 |
Why?
|
| Fitness Trackers | 1 | 2019 | 6 | 0.040 |
Why?
|
| Birth Weight | 2 | 1996 | 28 | 0.040 |
Why?
|
| Analgesics | 1 | 1999 | 48 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1999 | 46 | 0.040 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2019 | 14 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 118 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 66 | 0.030 |
Why?
|
| Substantia Nigra | 1 | 2019 | 68 | 0.030 |
Why?
|
| Cell Division | 1 | 1998 | 35 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2011 | 33 | 0.030 |
Why?
|
| Microglia | 1 | 2018 | 64 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2018 | 7 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 84 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1998 | 12 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 71 | 0.030 |
Why?
|
| Dementia, Vascular | 1 | 2018 | 19 | 0.030 |
Why?
|
| Brain Mapping | 2 | 2009 | 59 | 0.030 |
Why?
|
| Apoptosis | 1 | 1998 | 105 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1998 | 70 | 0.030 |
Why?
|
| Amyloidosis | 1 | 2017 | 4 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2016 | 5 | 0.030 |
Why?
|
| Maze Learning | 1 | 2016 | 5 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2016 | 8 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 5 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 3 | 0.030 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 1996 | 3 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 1996 | 16 | 0.030 |
Why?
|
| Arterioles | 1 | 2016 | 9 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 18 | 0.030 |
Why?
|
| Young Adult | 2 | 2010 | 863 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1996 | 29 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 97 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1995 | 5 | 0.030 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 11 | 0.030 |
Why?
|
| Biomechanical Phenomena | 3 | 2008 | 297 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 15 | 0.030 |
Why?
|
| Smoking | 1 | 1996 | 84 | 0.030 |
Why?
|
| Graft Rejection | 1 | 1995 | 30 | 0.030 |
Why?
|
| Renal Circulation | 1 | 1995 | 3 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 20 | 0.030 |
Why?
|
| Placebos | 1 | 1995 | 25 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1995 | 29 | 0.030 |
Why?
|
| Neuronal Plasticity | 2 | 2006 | 27 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 1995 | 30 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1995 | 55 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 21 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 108 | 0.030 |
Why?
|
| Sepsis | 1 | 1995 | 38 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 18 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 6 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 6 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 6 | 0.030 |
Why?
|
| Autoantigens | 1 | 2014 | 10 | 0.030 |
Why?
|
| Industry | 1 | 1994 | 3 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2014 | 112 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 85 | 0.030 |
Why?
|
| Catholicism | 1 | 2013 | 7 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2013 | 20 | 0.020 |
Why?
|
| Language Tests | 1 | 2013 | 16 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 25 | 0.020 |
Why?
|
| Clergy | 1 | 2013 | 39 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 117 | 0.020 |
Why?
|
| Cadaver | 1 | 2013 | 166 | 0.020 |
Why?
|
| R-SNARE Proteins | 1 | 2012 | 1 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 1 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 8 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 14 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 7 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 83 | 0.020 |
Why?
|
| Rest | 1 | 2012 | 19 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2012 | 30 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2004 | 100 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2011 | 2 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 15 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 14 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2010 | 9 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 13 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2003 | 99 | 0.020 |
Why?
|
| Mechanoreceptors | 1 | 2009 | 5 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 17 | 0.020 |
Why?
|
| Proprioception | 1 | 2009 | 8 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 25 | 0.020 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2009 | 11 | 0.020 |
Why?
|
| Child Development | 1 | 2010 | 52 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2009 | 19 | 0.020 |
Why?
|
| Joints | 1 | 2009 | 43 | 0.020 |
Why?
|
| Polysomnography | 1 | 2008 | 39 | 0.020 |
Why?
|
| Electromyography | 1 | 2008 | 22 | 0.020 |
Why?
|
| Wrist Joint | 1 | 2008 | 22 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 24 | 0.020 |
Why?
|
| Action Potentials | 1 | 2008 | 64 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2008 | 6 | 0.020 |
Why?
|
| Elbow Joint | 1 | 2008 | 52 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 38 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 201 | 0.020 |
Why?
|
| Isoprostanes | 1 | 2007 | 2 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 5 | 0.020 |
Why?
|
| Immunoassay | 1 | 2007 | 18 | 0.020 |
Why?
|
| Mutation | 1 | 2008 | 175 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2006 | 6 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2006 | 9 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 14 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2006 | 15 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2006 | 15 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2006 | 12 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 26 | 0.020 |
Why?
|
| Somatosensory Cortex | 1 | 2006 | 2 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 179 | 0.010 |
Why?
|
| Spain | 1 | 2005 | 4 | 0.010 |
Why?
|
| Speech | 1 | 2005 | 9 | 0.010 |
Why?
|
| Videotape Recording | 1 | 2005 | 7 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 20 | 0.010 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2005 | 4 | 0.010 |
Why?
|
| Anisotropy | 1 | 2005 | 25 | 0.010 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2005 | 36 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 2004 | 18 | 0.010 |
Why?
|
| Dopamine Agents | 1 | 2004 | 5 | 0.010 |
Why?
|
| Contrast Media | 1 | 2004 | 32 | 0.010 |
Why?
|
| Selection Bias | 1 | 2004 | 4 | 0.010 |
Why?
|
| Immobilization | 1 | 2003 | 6 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2003 | 11 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 38 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 126 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 281 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 2004 | 122 | 0.010 |
Why?
|
| Selegiline | 1 | 2002 | 1 | 0.010 |
Why?
|
| Tocopherols | 1 | 2002 | 4 | 0.010 |
Why?
|
| Drug Implants | 1 | 2001 | 2 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2001 | 19 | 0.010 |
Why?
|
| Estradiol | 1 | 2001 | 26 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2001 | 31 | 0.010 |
Why?
|
| Benzothiazoles | 1 | 2000 | 2 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 40 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2001 | 30 | 0.010 |
Why?
|
| Infertility, Male | 1 | 1979 | 2 | 0.010 |
Why?
|
| Infertility, Female | 1 | 1979 | 6 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Genes, bcl-1 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 1998 | 2 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 7 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1998 | 12 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1998 | 10 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1998 | 60 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 51 | 0.010 |
Why?
|
| Health Services Research | 1 | 1996 | 13 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 33 | 0.010 |
Why?
|
| Gestational Age | 1 | 1996 | 52 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 126 | 0.010 |
Why?
|
| Graft Survival | 1 | 1995 | 44 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 90 | 0.010 |
Why?
|
| Lifting | 1 | 1995 | 3 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1996 | 312 | 0.010 |
Why?
|
| Posture | 1 | 1995 | 20 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1995 | 214 | 0.010 |
Why?
|
| Spine | 1 | 1995 | 50 | 0.010 |
Why?
|
| Weight-Bearing | 1 | 1993 | 72 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1995 | 385 | 0.010 |
Why?
|